An Examination of Paraoxonase 1 Gene Polymorphism in Cases of Chronic Otitis Media

Year 2020, , 232 - 237, 25.04.2020

Kasım Durmuş , Hande Küçük Kurtulgan , Adem Bora Malik Ejder Yıldırım , Emine Elif Altuntaş

https://doi.org/10.32448/entupdates.594272

Abstract

Objective: Chronic otitis media (COM) is a multifactorial disorder, the pathogenesis of which has yet to be fully elucidated. Numerous aetiological factors, including genetics, eustachian tube dysfunction, autoimmunity, infection, osteoclastic activity, cytokines, endotoxins, and products of lipid peroxidation resulting from oxidative stress, have been proposed to explain the chronic inflammation which lies at the heart of the disorder. The aim of this study is to investigate a possible relationship between the pathogenesis of COM and polymorphism within the paraoxonase 1 (PON1) gene.
Methods: We investigated 49 patients admitted to the Otorhinolaryngology Department and diagnosed with COM between September and November 2017. The control group consisted of 51 healthy individuals. Polymerase chain reaction (PCR) – restriction fragment length polymorphism (RFLP) methods were used to genotype the PON1 Q192R (rs662) polymorphism.
Results: When the case and control groups were compared in terms of the existence of PON1 (Q192) polymorphism, there was no statistically significant difference between the groups (p=0.166, p>0.05). When intergroup comparison was performed on the type of PON1 (Q192) polymorphism, there was also no statistically significant difference (p=0.261, p>0.05).
Conclusion: The present study is the first known study in which PON1 polymorphism has been examined in cases of COM. The results of our study failed to indicate a statistically significant relationship between PON1 polymorphism and COM. However, it is important to note that the higher rate of 192RR polymorphism within the control group control may indicate a protective effect in COM.

Keywords

Otitis media, paraoxonase-1, genetic polymorphism, oxidative stress

References

• 1. Garça MF, Turan M, Avşar B, et al. The evaluation of oxidative stress in the serum and tissue specimens of patients with chronic otitis media. Clin Exp Otorhinolaryngol 2015;8:97-101.
• 2. Semaan MT, Megerian CA. The pathophysiology of cholesteatoma. Otolaryngol Clin North Am 2006;39:1143-59.
• 3. Louw L. Acquired cholesteatoma pathogenesis: stepwise explanations. J Laryngol Otol 2010;124:587-93.
• 4. Shibosawa E, Tsutsumi K, Takakuwa T, Takahashi S. Stromal expression of matrix metalloprotease-9 in middle ear cholesteatomas. Am J Otol 2000;21:621-4.
• 5. Yılmaz T, Kocan EG, Besler HT, Yilmaz G, Gursel B. The role of oxidants and antioxidants in otitis media with effusion in children. Otolaryngol Head Neck Surg 2004;131:797-803.
• 6. Karlidag T, Ilhan N, Kaygusuz I, Keleş E, Yalcin S. Comparison of free radicals and antioxidant enzymes in chronic otitis media with and without tympanosclerosis. Laryngoscope 2004;114:85-9.
• 7. Döner F, Delibas N, Dogru H, Yariktas M, Demirci M. The role of free oxygen radicals in experimental otitis media. J Basic Clin Physiol Pharmacol 2002;13:33-40.
• 8. Aktan B, Gundogdu C, Ucuncu H, Unal B, Sütbeyaz Y, Altas S. Anti-inflammatory effect of erythromycin on histamine-induced otitis media with effusion in guinea pigs. J Laryngol Otol 2004;118:97-101.
• 9. Hamzei M, Ventriglia G, Hagnia M, et al. Osteoclast stimulating and differentiating factors in human cholesteatoma. Laryngoscope 2003;113:436-42.
• 10. Chole RA, Faddis BT. Evidence for microbial biofilms in cholesteatomas. Arch Otolaryngol Head Neck Surg 2002;128:1129-33.
• 11. Peek FA, Huisman MA, Berckmans RJ, Sturk A, Van Loon J, Grote JJ. Lipopolysaccharide concentration and bone resorption in cholesteatoma. Otol Neurotol 2003;24:709-13.
• 12. Baysal E, Aksoy N, Kara F, et al. Oxidative stress in chronic otitis media. Eur Arch Otorhinolaryngol 2013;270:1203-8.
• 13. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003;54:371-92.
• 14. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
• 15. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-90.
• 16. Koc S, Aksoy N, Bilinc H, Duygu F, Uysal IÖ, Ekinci A. Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with chronic adenotonsillitis. Int J Pediatr Otorhinolaryngol 2011;75:1364-7.
• 17. Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene 2015;567:12-21.
• 18. Sarandöl E, Dirican M, Eröz E, Kırhan E, Serdar Z, Uncu G. Serum paraoxonase and arylesterase activities throughout normal pregnancy. Nobel Med 2011;7:49-55.
• 19. Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta 2009;410:1-12.
• 20. Gu HF, Mou M, Liang ZG, Sun C, Ren XY, Xiao YB. The association between paraoxonase 1 gene polymorphisms and polycystic ovarian syndrome. Cell Mol Biol (Noisy-le-grand) 2016;62:44-7.
• 21. Pappa KI, Gazouli M, Anastasiou E, Loutradis D, Anagnou NP. The Q192R polymorphism of the paraoxonase-1 (PON1) gene is associated with susceptibility to gestational diabetes mellitus in the Greek population. Gynecol Endocrinol 2017;33:617-20.
• 22. Ibrahim AA, El-Lebedy D, Ashmawy I, Hady MA. Association between paraoxonase-1 gene Q192R and L55M polymorphisms in systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS) in a population from Cairo of Egypt. Clin Rheumatol 2017;36:1305-10.
• 23. Turgut Cosan D, Colak E, Saydam F, et al. Association of paraoxonase 1 (PON1) gene polymorphisms and concentration with essential hypertension. Clin Exp Hypertens 2016;38:602-7.
• 24. Turan M, Ucler R, Aslan M, et al. Serum paraoxonase and arylesterase activities in patients with chronic otitis media. Redox Rep 2015;20:241-5.
• 25. Kotur-Stevuljevic J, Spasic S, Jelic-Ivanovic Z, et al. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin Biochem 2008;41:1067-73.
• 26. Shigemi H, Egashira T, Kurono Y, Mogi G. Role of superoxide dismutase in otitis media with effusion. Ann Otol Rhinol Laryngol 1998;107:327-31.
• 27. Yariktas M, Doner F, Dogru H, Yasan H, Delibas N. The role of free oxygen radicals on the development of otitis media with effusion. Int J Pediatr Otorhinolaryngol 2004;68:889-94.
• 28. Agachan B, Yilmaz H, Karaali Z, Isbir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct 2004;22:163-8.